TROP2 overexpression
|
NSCLC
|
TROP2 overexpression
|
NSCLC
|
DS-1062a Sensitive: C3 – Early Trials
|
DS-1062a Sensitive: C3 – Early Trials
|
TROP2 overexpression
|
Triple Negative Breast Cancer
|
TROP2 overexpression
|
Triple Negative Breast Cancer
|
sacituzumab govitecan-hziy Sensitive: D – Preclinical
|
sacituzumab govitecan-hziy Sensitive: D – Preclinical
|
TROP2 overexpression
|
Triple Negative Breast Cancer
|
TROP2 overexpression
|
Triple Negative Breast Cancer
|
BAT8003 Sensitive: D – Preclinical
|
BAT8003 Sensitive: D – Preclinical
|
TROP2 overexpression
|
Endometrial Cancer
|
TROP2 overexpression
|
Endometrial Cancer
|
sacituzumab govitecan-hziy Sensitive: D – Preclinical
|
sacituzumab govitecan-hziy Sensitive: D – Preclinical
|